Search in:

Journal of Market Access & Health Policy Volume 5, 2017 - Issue 1

Journal homepage

Open access

8,608

Views

CrossRef citations to date

Altmetric

Original Articles

Key drivers for market penetration of biosimilars in Europe

Cécile RémuzatPricing and Market Access Department, Creativ-Ceutical, Paris, FranceCorrespondence[email protected]

Julie DoreyHEOR Department, Creativ-Ceutical, Paris, France

Olivier CristeauHEOR Department, Creativ-Ceutical, Paris, France

Dan IonescuGlobal Pricing and Market Access Biopharmaceuticals Department, Sandoz International GmbH, Holzkirchen, Germany

Guerric RadièreGlobal Pricing and Market Access Biopharmaceuticals Department, Sandoz International GmbH, Holzkirchen, Germany

Mondher ToumiFaculté de Médecine, Laboratoire de Santé Publique, Aix-Marseille Université, Université de la Méditerranée, Marseille, France

Article: 1272308 | Published online: 30 Jan 2017

Cite this article
https://doi.org/10.1080/20016689.2016.1272308
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

Figures & data

Table 1. List of biosimilars approved by the European Medicines Agency (as of March 2016) [Citation1].

Download CSV Display Table

Table 2. List of best-selling biologics with patent expiry in the years to come [Citation2,Citation3].

Download CSV Display Table

Table 3. Selection of the 10 EU countries members of the Organisation for Economic Co-operation and Development (OECD) having the highest pharmaceutical expenditure [Citation23,Citation24].

Download CSV Display Table

Table 4. Analogue products considered in the study.

Download CSV Display Table

Table 5. Estimations of generic uptake versus off-patent market (volume) and generic discounts versus reference product used in the regression model.

Download CSV Display Table

Table 6. Overview of key incentive policies in the 10 selected EU countries for biosimilars (Con’t) (as of November 2015).

Display Table

Table

Display Table

Figure 1. Total 2014–2015 (Q1/Q2) sales in volume of biosimilar and originator products by country and by therapeutic classes.

Figure 2. Average biosimilar price discount by country in (%) over originator products.

Table 7. Selected generalised linear model results.

Download CSV Display Table

Table 8. Date of entry in the EU and GDP per capita of 10 selected EU countries [Citation53,Citation63].

Download CSV Display Table

European Medicines Agency Website. Medicines [Internet]; [ cited 2016 Jan 18]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&mid

Google Scholar

IMS Health. Assessing biosimilar uptake and competition in European markets [Internet]. [ updated 2014 Oct; cited 2016 Jan 18]. Available from: https://www.imshealth.com/files/web/IMSH%20Institute/Healthcare%20Briefs/Assessing_biosimilar_uptake_and_competition_in_European_markets.pdf

Google Scholar

GaBi Online. US$67 billion worth of biosimilar patents expiring before 2020 [Internet]. [ updated 2014 Jan 20; cited 2016 Jan 18]. Available from: http://www.gabionline.net/Biosimilars/General/US-67-billion-worth-of-biosimilar-patents-expiring-before-2020

Google Scholar

OECD Health Data. Health expenditure and financing: OECD Health Statistics (database) [Internet]. [ updated 2014 Jun 30; cited 2016 Jan 18]. doi: 10.1787/pharmexpcap-table-2014-1-en.

Google Scholar

OECD Data. Demography, Population [Internet]. 2012 [ cited 2016 Jan 18]. Available from: https://data.oecd.org/pop/population.htm

Google Scholar

National Institute for Health and Disability Insurance (INAMI). Reference reimbursement system [Internet]. [ updated 2015 Mar 25; cited 2016 Jan 18]. Available from: http://www.inami.fgov.be/fr/themes/cout-remboursement/par-mutualite/medicament-produits-sante/remboursement/specialites/Pages/systeme-remboursement-reference.aspx#.Vqfx-OgrLIU

Google Scholar

French Generic Medicines Association (GEMME). Pricing and reimbursement of generics [Internet]. [ cited 2016 Jan 18]. Available from: http://www.medicamentsgeneriques.info/son-cadre-reglementaire-et-sanitaire/prix-et-admission-au-remboursement/

Google Scholar

European Observatory on Health Systems and Policies. Health Systems in Transition (HiT) profile of Germany [Internet]. 2014 [ cited 2016 Jan 18]. Available from: http://www.hspm.org/countries/germany28082014/livinghit.aspx?Section=5.6%20Pharmaceutical%20care&Type=Section

Google Scholar

Anastasaki E, Bradshaw S, Proach J, et al. The Geek Healthcare reform after Troika: the potential impact on global pricing and access strategy. Poster, ISPOR congress, 17th Annual European Congress, Amsterdam, The Netherlands [Internet]. [ updated 2014 Nov; cited 2016 Jan 18]. Available from: http://www.ispor.org/research_pdfs/48/pdffiles/PHP152.pdf

Google Scholar

WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies. Hungary Poster [Internt]. 2012 [ cited 2016 Jan 18]. Available from: http://whocc.goeg.at/Literaturliste/Dokumente/CountryInformationPosters/10e_HU_Poster_NemethGergely_2012.pdf

Google Scholar

Italian Ministry of Health. Decree ”Criteri di individuazione degli scaglioni per la negoziazione automatica dei generici e dei biosimilari” [Internet]. [ updated 2013 Apr 4; cited 2016 Jan 18]. Available from: http://www.gazzettaufficiale.it/eli/id/2013/06/06/13A04795/sg

Google Scholar

GaBi. Policies and legislation. Poland [Internet]. [ updated 2013 Nov 26; cited 2016 Jan 18]. Available from: http://www.gabionline.net/layout/set/print/Country-Focus/Poland/Policies-and-Legislation

Google Scholar

Aeseg website [Internet]. [ cited 2016 Jan 18]. Available from: http://www.aeseg.es/es/preguntas-frecuentes-medicamentos-genericos

Google Scholar

TLV website. Ceiling price [Internet]. [ Updated 2015 Oct 28; cited 2016 Jan 18]. Available from: http://www.tlv.se/lakemedel/takpriser/

Google Scholar

Toumi M, Rémuzat C. EU Pharmaceutical expenditure forecast [Internet]. [ updated 2012 Nov 26; cited 2016 Jan 18]. Available from: http://ec.europa.eu/health/healthcare/docs/creativ_ceutical_eu_pharmaceutical_expenditure_forecast.pdf

Google Scholar

OECD. Health at a Glance 2015: OECD Indicators. Paris: OECD Publishing; 2015. DOI:10.1787/health_glance-2015-en

Google Scholar

Läkemedelsverkets. Substitutable Medicinal Products [Internet]. [ updated 2015 Sep 30; cited 2016 Jan 18]. Available from: https://lakemedelsverket.se/upload/halso-och-sjukvard/forskrivning/utbytbarhet/Utbytbara%20l%C3%A4kemedel%20(hela%20listan)%202015-09-30.pdf

Google Scholar

European.eu. Member countries of the EU (year of entry) [Internet]; [ cited 2016 Jan 18]. Available from: https://europa.eu/european-union/about-eu/countries_en

Google Scholar

Related Research Data

Source: Springer Science and Business Media LLC

Regulation of biosimilar medicines and current perspectives on interchangeability and policy

Source: Springer Science and Business Media LLC

Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting

Source: Springer Science and Business Media LLC

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Source: Frontiers Media SA

Comparison of Utilization Trends between Biosimilars and Generics: Lessons from the Nationwide Claims Data in South Korea

Source: Springer Science and Business Media LLC

Linking provided by

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Key drivers for market penetration of biosimilars in Europe

Table 1. List of biosimilars approved by the European Medicines Agency (as of March 2016) [Citation1].

Table 2. List of best-selling biologics with patent expiry in the years to come [Citation2,Citation3].

Table 3. Selection of the 10 EU countries members of the Organisation for Economic Co-operation and Development (OECD) having the highest pharmaceutical expenditure [Citation23,Citation24].

Table 4. Analogue products considered in the study.

Table 5. Estimations of generic uptake versus off-patent market (volume) and generic discounts versus reference product used in the regression model.

Table 6. Overview of key incentive policies in the 10 selected EU countries for biosimilars (Con’t) (as of November 2015).

Table 7. Selected generalised linear model results.

Table 8. Date of entry in the EU and GDP per capita of 10 selected EU countries [Citation53,Citation63].

Related Research Data

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Key drivers for market penetration of biosimilars in Europe

Figures & data

Table 1. List of biosimilars approved by the European Medicines Agency (as of March 2016) [Citation1].

Table 2. List of best-selling biologics with patent expiry in the years to come [Citation2,Citation3].

Table 3. Selection of the 10 EU countries members of the Organisation for Economic Co-operation and Development (OECD) having the highest pharmaceutical expenditure [Citation23,Citation24].

Table 4. Analogue products considered in the study.

Table 5. Estimations of generic uptake versus off-patent market (volume) and generic discounts versus reference product used in the regression model.

Table 6. Overview of key incentive policies in the 10 selected EU countries for biosimilars (Con’t) (as of November 2015).

Table 7. Selected generalised linear model results.

Table 8. Date of entry in the EU and GDP per capita of 10 selected EU countries [Citation53,Citation63].

Related Research Data

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date